Under the global license, Glaxo plans to use the database, PathArt, for its drug discovery research.
PathArt contains more than 1,200 signal-, metabolic-, and disease-specific pathways that have been manually curated. These pathways cover a number of diseases, including different types of cancer, arthritis, Alzheimer's disease, asthma, multiple sclerosis, Parkinson's disease, diabetes, and atherosclerosis.